CRL

Business Profile & Competitive Position

Charles River Laboratories International, Inc. (CRL) sits in the Healthcare sector, specifically the Medical - Diagnostics & Research industry. In plain terms, it is a full-service, non-clinical drug-development partner: it supplies research model technologies, runs discovery and safety assessment work (both GLP and non-GLP), and provides manufacturing support products and services that help move therapies from target identification through non-clinical testing and toward product release. Its role is largely “upstream” in the pharmaceutical and biotech pipeline, before compounds reach the clinic in most cases.

The financial footprint of that position, however, is worth reading closely. The company currently carries a negative net margin of -6.0% and a negative return on equity of -7.7%. Those figures do not describe a business currently extracting excess returns from a deep competitive moat; they describe one absorbing cost pressures, restructuring charges, acquisition amortization, or some mix of operating headwinds. With a beta of 1.38, the stock has also moved materially more than the broader market, which is consistent with a services model tied to biotech funding cycles, client R&D budgets, and capital-market appetite for early-stage drug development. None of this confirms or denies a durable moat, but it does mean the margin and ROE data should be central to any moat discussion rather than treated as an afterthought.

Financial Posture

Charles River Laboratories’ market capitalization stands at $13.8 billion. The P/E ratio is -59.2, a direct consequence of negative trailing earnings in the current data set. A negative P/E ratio is not intrinsically good or bad; it simply flags that the company recorded net losses over the period used in the calculation. Paired with the -6.0% net margin and -7.7% ROE, the valuation message is that investors are pricing the business off future earnings power, asset values, or recovery expectations rather than off current profitability.

The beta of 1.38 reinforces that this is a higher-volatility equity within Healthcare. For context, the current share price is $286.64, while the 50-day exponential moving average is $231.48. The stock is trading well above that moving average, and the RSI reading of 78.5 puts it in technically overbought territory by the standard 70-threshold definition. Those price and momentum figures do not imply any directional call, but they are relevant for understanding how fast the stock has re-priced versus its near-term trend.

Strategic Priorities & Outlook

The company’s most recent 10-K filing lays out a clear operational agenda. First, it describes itself as a leading, full-service, non-clinical global drug development partner and organizes the business into three reportable segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. In 2025, total revenue was $4.0 billion, with DSA contributing 59.8%, RMS contributing 21.1%, and Manufacturing contributing 19.1%. Geography and infrastructure matter too: CRL currently operates in more than 120 sites across more than 20 countries.

Management’s near-term priorities include optimizing the global footprint by closing or consolidating approximately 12 additional sites over the next two years, principally within the DSA and RMS segments. It is also integrating Discovery Services and Safety Assessment into one overarching DSA organization with a combined sales force and leadership approach, a move aimed at presenting a unified scientific partner rather than separate service lines. Beyond cost and integration, the company wants to expand Biologics Testing Solutions service offerings and facilities in the U.S. and Europe, and it continues to position itself as the scientific partner of choice through a comprehensive, integrated portfolio. In January 2026, it acquired certain assets of K.F. (Cambodia) Ltd., a provider of non-human primates, to support DSA supply operations and RMS third-party sales.

Macro & Geopolitical Exposure

As a Healthcare company in Medical - Diagnostics & Research with a global, multi-site operating base, Charles River faces exposures that are typical of the contract research and research-model space. Regulatory risk is front and center: much of its safety assessment work is governed by GLP and other FDA, EMA, and equivalent standards around the world, so changes in non-clinical testing requirements or agency enforcement can shift demand and compliance costs. Trade policy matters both directions: the company sources and distributes biologic materials, animals, and specialized products across borders, and tariffs or export controls on research models and related supplies can affect margins and project timelines. Currency exposure follows naturally from a 20-plus-country footprint, since revenue and costs in different currencies create translation and transaction effects.

Supply-chain sensitivity is also inherent to the model. Non-human primate availability, vivarium capacity, and specialized reagent supply have all been volatile themes across the contract research organization industry, and the January 2026 Cambodia acquisition can be read partly against that backdrop. Finally, client demand in this segment is tied to biotech and large pharma R&D budgets, which ebb and flow with capital markets, interest rates, and therapeutic cycle trends. None of these exposures are unique to CRL, but they are the macro dimensions most relevant to its industry classification.

Recent Developments

The most recent headlines capture a stock that has become notable to traders and investors. On August 11, 2026, defenseworld.net reported that CAO Michael Gunnar Knell sold 6,645 shares. The same day, defenseworld.net also carried a headline noting that Charles River Laboratories had set a new 52-week high. On August 10, 2026, zacks.com published an “International Markets and Charles River (CRL): A Deep Dive for Investors.” Earlier, on August 6, 2026, 247wallst.com listed Charles River among Thursday’s top Wall Street analyst research calls. Those items do not carry any management quotes or项目 updates, but they do show a ticker drawing attention after a strong price run and an earnings beat on August 5.

Earnings Behavior & Post-Earnings Drift

Charles River Laboratories has a strong recent earnings record. Over the last eight reported quarters, it beat consensus EPS estimates in all eight, for a 100% beat rate, with an average earnings surprise of 9.3%. The average five-day price move in the trading sessions after those earnings reports was +1.24%, classified as an upward post-earnings drift.

The most recent four quarters illustrate how varied the price reaction can be even when the EPS number tops expectations:

• August 5, 2026: actual EPS of $3.02 versus an estimate of $2.74, a 10.2% surprise. The stock rose 1.84% the next day and 9.07% over the next five days.
• May 7, 2026: actual EPS of $2.06 versus an estimate of $1.96, a 5.1% surprise. The stock fell 2.23% the next day and 12.42% over the following five days.
• February 18, 2026: actual EPS of $2.39 versus an estimate of $2.33, a 2.6% surprise. The stock rose 3.95% the next day and 6.05% over five days.
• November 5, 2025: actual EPS of $2.43 versus an estimate of $2.32, a 4.7% surprise. The stock rose 1.90% the next day and 2.27% over five days.

Looking ahead, the next scheduled earnings release is November 4, 2026, before the market open, with a consensus EPS estimate of $2.97. The 100% beat rate tells you that the company has consistently cleared the official estimate; the spread in next-day and five-day moves tells you that beating the estimate is no guarantee of short-term price direction, because guidance, margins, segment commentary, and broader market tone all factor into the reaction.

For readers who want to go deeper than these summary statistics, the full institutional verdict—including analyst revision trends, target price dispersion, and pre-earnings positioning—offers the next logical layer of insight.